March 17, 2020 9:58am

A scorecard of earnings of 35 covered  companies

(1 more - ATHX of 28 reporting)

The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"

 


COMPANY Q4/19

SYMBOL NET INCOME Q4/19 LOSS Q4/19 LPS Q4/19 CASH RUNWAY
Aduro Biotech, Inc. ADRO  

-$19.4 M

-$82.4 M (FY19) with -$5 M

discontinued progam loss

-$0.24 $213.6 M 2021
Alnylam Pharmaceuticals ALNY  

-$221.2 M

-$886.1 M, FY19

-$1.98

-$6.50, FY19

$1.55 B

 Not (N/N)

needed

Applied Genetic Technologies AGTC          
Athersys, Inc. ATHX  

-$9.9 M

-$44.6 M (FY19)

-$0.06

-$0.29

$44.6 M Q3/2021
Adverum Biotechnologies, Inc. ADVM  

-$18.9 M

-$64.4 M (FY19)

-$0.29

-$1.01

$166 M 2022
Audentes Therapeutics BOLD          
AxoGen, Inc. AXGN  

-$7 M

-$29 .1 M

-$0.18

-$0.74

$102.5 M N/N
Bellicum Pharmaceuticals BLCM  

-$29 M

-$112.5 M (FY19)

-$5.82

-$24.01

$93.8 M Q2/2021
BioLife Solutions, Inc. BLFS

+$481 K or +$0.02

+$11.1 M (FY19) or +$0.42

    $6.448 M N/N
Biostage, Inc. BSTG          
bluebird bio BLUE  

-$323.3 M

-$789.6 M,FY19

  $124 B 2022
Brainstorm Cell Therapeutics BCLI  

No Q4

-$23.2 M, FY19

No Q4

-$1.06, FY19

$600 K 2020
Caladrius Biosciences. CLBS  

-$5 M

-$19.4 M (FY19)

-$0.47

-$1.88 (FY19)

$25.16 M Q2/2021
Cellectis SA CLLS  

-$37 M

-$102 m (FY19)

-$0.88

-$2.41 (FY19)

$364 M 2022
CRISPR Therapeutics CRSP

+$30.5 M or +$0.51 per share

+$6.9 M or +$1.17 per share  (FY19)

 

 

  $943.8 M 2023
Editas Medicine EDIT  

-437.8 M

-$133.7 M

-$0.74

-$2.68

+$457.1 M 2022
Fate Therapeutics FATE  

-$28.3 M

-$98.14 M (FY19)

 

-$0.37

-$1.44 (FY19)

+$260.9 M 2021
Global Blood Therapeutics GBT  

-499.5 M (Q4)

-$266.76 M (FY19)

 

-$1.73

(Q4) 

-$4.71

(FY19)

$695 M

$150 M loan (Pharmakon Advisors)

2022
Homology Medicine FIXX  

-$24.2 M

$103.9 M (FY19)

-$0.55

-$2.47

$262.4 M Q4/2021
Intellia Therapeutics NTLA  

-$28.3 M

-$683.5 M (FY18)

-$0.51

-$2.11 (FY19)

$284.5 M

ATM usuage of $124.9 M

2021
Precigen (fomerly Intrexon (XON) XON  

-$169.2 M

(FY19)

-$322.3 M from discontinued operations +$70.4 M non-cash charges

-$1.09

(FY19)

-$2.09

+$75.1 M 2020
Ionis Pharmaceuticals IONS

+$204 M or +$1.31 per share

$303 M or $2.12 per share (FY19)

    $2.5 B N/N
Mesoblast Limited MESO  

-$24.58 M(Q4)

-$30.06 M (FY 6 mo)

 

 

-$4.60(Q4)

-$5.82

$81.3 M

Acess to $62.5 Mfrom existing financial faclities

2021
MiMedx Group, Inc MDXG          
Pluristem Therapeutics, Inc. PSTI          
ReNeuron Group PLC RENE.L          
Regenxbio RGNX  

 

-$26.5 M (q4)

-$94.7M  

(FY19)

-$0.72

-$2.58

$400 M 2022
Sage Therapeutics SAGE  

-$168.7 M (Q4)

-$680.2 M (FY19)

-$3.25

-$13.38

$1 B N/N
Sangamo Biosciences, Inc. SGMO

+$4.6 M or $0.04 per share (Q4)

-$95.2 M or -$0.85 per share (FY19)

    $3.85 M 2023
Solid Biosciences SLDB  

-$31.9 M

-$117.2 M (FY19)

No Q4 #

-$2.91

$83.5 M 2021
Stemline Therapeutics, Inc. STML  

-$17.7 M

-$76.79 M (FY19)

-$0.38

-$1.83

$164.4 Q2/2021
Ultragenyx RARE  

-$93.8 M

-$402.7 M  (FY19)

-$1.62

-$7.12 

$760.4 M 2022
uniQure N.V. QURE  

-$124.2 M (FY19)

-$3.11

FY19

$377.8 M 2022
Verastem, Inc. VSTM  

-$38.8 M

-$126 M

-$0.51

-$1.69

$113 M add

$92 M (pp on 3/3/2020) 

Q4/2021
Vericel Corporation VCEL +$9.5 M or +$0.20 per share

 

-$9.7 M (FY19)

 

-$0.22 (FY19)

$79 M 2022
Voyager Therapeutics VYGR  

-$12.6 M

-$43.6 M (FY19)

-$0.34

-$1.21 (FY19)

$281.5 M mid-2022